Please login to the form below

Not currently logged in

Bayer acquires rights to SciLin insulin

Bayer Schering Pharma has acquired to exclusive rights to market and distribute Bioton's SciLin insulin in China

Bayer Schering Pharma has acquired to exclusive rights to market and distribute Bioton's SciLin insulin in China.

The deal involves an up-front payment of €31m to the Polish insulin producer and will guarantee a secured supply of the insulin product for the next 15 years for exclusive commercial delivery by Bayer in the Chinese market.

Janusz R Guy, CEO of Bioton said: "With this agreement for long-term collaboration, Bioton has [realised] one of its strategic goals to develop its strong international position on growing insulin markets via alliances with leading pharmaceutical companies."

There are around 40 million diabetes sufferers in China and insulin has a projected annual growth rate of more than 40 per cent.

"Today, Bayer is already a top ranking international pharmaceutical company in China with our pharmaceutical Glucobay for treatment of type 2 diabetes being the most successful product. Through the planned distribution of SciLin, we will further supply patients suffering from diabetes, and will expand our position in this very promising growth market," said Andreas Fibig, CEO of Bayer Schering Pharma.

9th July 2009


Featured jobs

Subscribe to our email news alerts


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...